All In Biotech

Drug Trial Radar · NCT02393248

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)

Last checked: Nov 19, 2026Latest source record: Jan 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

201

Actual

Start

Feb 27, 2015

Primary completion

Dec 17, 2021

Study completion Dec 17, 2021

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Mar 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).

Conditions

  • Lung Cancer
  • Solid Tumor
  • Gastric Cancer
  • Urothelial Cancer
  • Endometrial Cancer
  • Multiple Myeloma
  • Myeloproliferative Neoplasms
  • Breast Cancer
  • Cholangiocarcinoma
  • UC
  • MPN

Interventions

  • PemigatinibDrug

  • GemcitabineDrug

  • PembrolizumabDrug

  • DocetaxelDrug

  • TrastuzumabDrug

  • RetifanlimabDrug

  • CisplatinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)Time frame: up to 763 days
  2. Part 3: Number of Participants With Any TEAETime frame: up to 869 days
  3. E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
  4. EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
  5. Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles
  6. Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2Time frame: predose on Days 1 and 14 of Cycle 1; anytime during visit on Day 1 of Cycle 2 and all subsequent cycles

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama At Birmingham Comprehensive Cancer Center

    Birmingham, Alabama

  • Cedars-Sinai Medical Center

    West Hollywood, California

  • Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • Hematology Oncology Associates of the Tr

    Port Saint Lucie, Florida

  • Emory University - Winship Cancer Institute

    Atlanta, Georgia

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • John Theurer Cancer Center, Hackensack University Medical Center

    Hackensack, New Jersey

  • Northwell Health - Monter Cancer Center

    New Hyde Park, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Ohio State University - Wexner Medical Center

    Columbus, Ohio

  • Signal Point Clinical Research Center

    Middletown, Ohio

  • Greenville Health System Cancer Institute

    Greenville, South Carolina

  • Mary Crowley Cancer Research Ctr

    Dallas, Texas

  • Md Anderson Cancer Center

    Houston, Texas

  • South Texas Accelerated Research Therapeutics

    San Antonio, Texas

  • Baylor Scott & White Health

    Temple, Texas

  • The Finsen Centre National Hospital

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.